A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +53 locations
Conditions: Obesity, Overweight
Register for Updates
Evaluation of A Clinical Diagnostic Test for CRDS
NCT06188689
Recruiting
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: University of Washington, Seattle, Washington +8 locations
Conditions: Calcium Release Deficiency Syndrome (CRDS)
Register for Updates
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
NCT06320717
Recruiting
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +1 locations
Conditions: Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249
Recruiting
This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: GSK Investigational Site, Anniston, Alabama +81 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504
Recruiting
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: GSK Investigational Site, Bakersfield, California +49 locations
Conditions: Hepatitis B
Register for Updates
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282
Recruiting
This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.
Gender:
ALL
Ages:
5 days and above
Trial Updated:
04/24/2025
Locations: UC Davis Health, Sacramento, California +8 locations
Conditions: Patent Ductus Arteriosus (PDA)
Register for Updates
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT06704191
Recruiting
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Non-Muscle Invasive Bladder Carcinoma, Stage I Bladder Cancer AJCC V8, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Register for Updates
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912
Recruiting
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland +2 locations
Conditions: Lung Neoplasm Malignant
Register for Updates
A Study of PHST001 in Advanced Solid Tumors
NCT06840886
Recruiting
PHST001-101 is a multicenter, open-label, Phase 1 study of PHST001 in patients with advanced solid tumors. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced relapsed and/or refractory solid tumors. The study's primary object is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumors
Register for Updates
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
NCT06954805
Recruiting
The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone. This study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, h... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/24/2025
Locations: Stanford Medical Center, Stanford, California +1 locations
Conditions: Lymphoma, Lymphoma, B-Cell
Register for Updates
Identifying Genetic Causes of IC/BPS
NCT00389142
Recruiting
Interstitial cystitis (IC), also called Bladder Pain syndrome (BPS) is a common condition with no known cause or cure. Twin studies and family accounts have suggested that the condition may be genetic or passed down (inherited) from one generation to another. In this study, we are collecting genetic material via blood or saliva and medical information from families in North America in an attempt to identify genetic factors that may cause IC/BPS. We are enrolling inviduals with IC/BPS and their... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
04/24/2025
Locations: Boston Children's Hospital (BCH), Boston, Massachusetts
Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Register for Updates
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
NCT03824145
Recruiting
This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Loyola University, Maywood, Illinois +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates